A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

NCT07675811 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: REGN-2Cat
DRUG: Freneslerbart
DRUG: Mevonlerbart
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals